Register entry

Acadia Pharmaceuticals Inc.

Registered sites
0
Drug products
6
Live patents
59
Countries
0
Base
Unknown
Sites

Facilities

0

No registered facilities

This company holds drug listings or approvals but operates no registered establishment of its own, which is normal for an NDA holder that outsources manufacturing.

Exclusivity

Patents

59

Unexpired Orange Book patents where this company is the application holder.

ProductActive ingredientExpiry
DAYBUETROFINETIDEJan 2032
DAYBUETROFINETIDEJul 2032
DAYBUETROFINETIDEAug 2040
DAYBUETROFINETIDEFeb 2041
DAYBUETROFINETIDEJul 2042
DAYBUETROFINETIDEJan 2043
DAYBUE STIXTROFINETIDEJan 2032
DAYBUE STIXTROFINETIDEJul 2032
DAYBUE STIXTROFINETIDEAug 2040
DAYBUE STIXTROFINETIDEFeb 2041
DAYBUE STIXTROFINETIDEJul 2042
DAYBUE STIXTROFINETIDEJan 2043
NUPLAZIDPIMAVANSERIN TARTRATEAug 2026
NUPLAZIDPIMAVANSERIN TARTRATEJun 2028
NUPLAZIDPIMAVANSERIN TARTRATEDec 2028
NUPLAZIDPIMAVANSERIN TARTRATEApr 2030
NUPLAZIDPIMAVANSERIN TARTRATEOct 2030
NUPLAZIDPIMAVANSERIN TARTRATEMar 2037
NUPLAZIDPIMAVANSERIN TARTRATESept 2037
NUPLAZIDPIMAVANSERIN TARTRATEAug 2038
NUPLAZIDPIMAVANSERIN TARTRATEFeb 2039
Catalogue

Marketed products

6

Showing 6 of 6.

BrandGeneric nameFormCategory
DaybuetrofinetideSOLUTIONNDA
Daybue StixtrofinetideFOR SOLUTIONNDA
Daybue StixtrofinetideFOR SOLUTIONNDA
Daybue StixtrofinetideFOR SOLUTIONNDA
NUPLAZIDpimavanserin tartrateTABLET, COATEDNDA
NUPLAZIDpimavanserin tartrateCAPSULENDA
Provenance

Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.